



Notice of Changes in Executive Management at Sosei

Tokyo, Japan and London, UK, 4 June 2018 – Sosei Group Corporation (“Sosei” or the “Company”; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, today announces the resignation of an Executive Officer. The details are as follows.

1. Name of the Executive Officer to Resign

Mr. Andrew Oakley, Executive Officer, Executive Vice President and CFO

2. Effective Date of Resignation

4 June 2018

3. Reason for Resignation

For personal reasons

4. Other Information

The Board of Directors, at its meeting held on 4 June 2018, appointed Mr. Chris Cargill, currently Senior Vice President of Corporate Strategy and Head of Investor Relations and Corporate Communications, as the Company’s interim CFO.

Mr. Cargill joined Sosei in September 2017 and has more than a decade of experience in corporate finance divisions at major companies around the world.

The Company will make an announcement regarding a new CFO as soon as the appointment is made.

-Ends-

Enquiries:

Sosei Group

Investor Relations and Corporate Communications

IR@sosei.com

+81 (0) 3 5210 3290

Citigate Dewe Rogerson (for international media)

Mark Swallow

David Dible

sosei@citigatedewerogerson.com

+44 (0) 20 7638 9571

About Sosei

Sosei is an international biopharmaceutical company focused on the design and development of new medicines originating from its proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. The Company is advancing a broad and deep pipeline of partnered and wholly owned product candidates in multiple therapeutic areas, including CNS, cancer, metabolic diseases and other rare/specialty indications. The Company’s leading clinical programs include a proprietary Phase 2 candidate for dementia



with Lewy bodies (DLB) in Japan, together with partnered candidates aimed at the symptomatic treatment of Alzheimer's disease (with Allergan) and immuno-oncology approaches to treat cancer (with AstraZeneca). Sosei's additional partners and collaborators include Novartis, Pfizer, Daiichi-Sankyo, PeptiDream, Kymab and MorphoSys. The Company is headquartered in Japan with R&D facilities in the UK.